Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Anti-Cancer Drug Design

• Publication date

  1999-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 10500494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.

  1998cited by this paper
• A survey of 178 NF-Y binding CCAAT boxes.

  1998cited by this paper
• Zinc fingers are sticking together.

  1998cited by this paper
• Cloning and expression of human NF-YC.

  1997cited by this paper
• Crystal structure of the nucleosome core particle at 2.8 Å resolution

  1997cited by this paper
• DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.

  1996cited by this paper
• Cell Cycle Regulation of E2F Site Occupation in Vivo

  1996cited by this paper
• Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription.

  1995cited by this paper
• The amino-terminal tails of the core histones and the translational position of the TATA box determine TBP/TFIIA association with nucleosomal DNA.

  1995cited by this paper
• Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA.

  1994cited by this paper
• Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMR.

  1994cited by this paper
• Modulation of transcription factor--DNA interactions by anticancer drugs.

  1994cited by this paper
• Maf nuclear oncoprotein recognizes sequences related to an AP-1 site and forms heterodimers with both Fos and Jun

  1994cited by this paper
• The human A-myb protein is a strong activator of transcription.

  1994cited by this paper
• Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins.

  1993cited by this paper
• Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata.

  1993cited by this paper
• Distamycin‐induced inhibition of homeodomain‐DNA complexes.

  1992cited by this paper
• O6-methylguanine inhibits the binding of transcription factors to DNA.

  1991cited by this paper
• Sequence-specific DNA binding by the c-Myc protein.

  1990cited by this paper
• Transcription factor E2F is required for efficient expression of the hamster dihydrofolate reductase gene in vitro and in vivo

  1989cited by this paper
• Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements.

  1989cited by this paper
• Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

  1988cited by this paper
• Transient accumulation of c-fos RNA following serum stimulation requires a conserved 5' element and c-fos 3' sequences.

  1985cited by this paper
• Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins

  1985cited by this paper
• Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

  1983cited by this paper
• A new procedure for purifying histone pairs H2A + H2B and H3 + H4 from chromatin using hydroxylapatite.

  1979cited by this paper

• Exploiting divergent mechanisms of trabectedin for bone tumors

  2025cites this paper
• Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?

  2024cites this paper
• Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment—Progresses in Their Use in Combined Cancer Therapy

  2024cites this paper
• Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets

  2022cites this paper
• Marine Niche: Applications in Pharmaceutical Sciences: Translational Research

  2020cites this paper
• Enriching cancer pharmacology with drugs of marine origin

  2020cites this paper
• Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response.

  2020cites this paper
• A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.

  2019cites this paper
• The FUS-DDIT 3 Interactome in Myxoid Liposarcoma 1

  2019cites this paper
• The FUS-DDIT3 Interactome in Myxoid Liposarcoma

  2019cites this paper
• Challenging transcription by DNA‐binding antitumor drugs

  2018cites this paper
• HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance

  2018cites this paper
• Marine drugs for cancer: surfacing biotechnological innovations from the oceans

  2018cites this paper
• Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance

  2017influential citation
• Identification of effective new drugs combinations exploiting the ability of trabectedin to modulate transcription

  2017cites this paper
• NF-Y in cancer: Impact on cell transformation of a gene essential for proliferation.

  2017cites this paper
• Unique features of trabectedin mechanism of action

  2016cites this paper
• Anticancer agent-based marine natural products and related compounds

  2015cites this paper
• Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts

  2015cites this paper
• Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression.

  2015cites this paper
• Trabectedin in Soft Tissue Sarcomas

  2015cites this paper
• Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.

  2015cites this paper
• P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae

  2015cites this paper
• Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy.

  2014cites this paper
• Mode of action of trabectedin in myxoid liposarcomas

  2014cites this paper
• Cancer wars: natural products strike back

  2014cites this paper
• From old alkylating agents to new minor groove binders.

  2014cites this paper
• Efficacy of Trabectedin in Patients with Advanced or Metastatic Alveolar Soft-Part Sarcoma

  2012cites this paper
• Mode of action of trabectedin in human mixoid liposarcoma growing in immunodeficient mice : evidence that the drug acts by displacing FUS-CHOP chimeric protein from its target promoters

  2012cites this paper
• TRABECTEDIN: A NOVEL MOLECULAR THERAPEUTIC IN CANCER

  2011cites this paper
• Activity of trabectidin in desmoplastic small round cell tumor

  2011cites this paper
• Management of Ovarian Cancer and Soft Tissue Sarcoma: Focus on Trabectedin

  2011cites this paper
• Ecteinascidin-743 (Yondelis®), Aplidin®, and Irvalec®

  2011cites this paper
• Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.

  2011cites this paper
• New therapies in soft tissue sarcoma

  2010cites this paper
• A Review of Trabectedin (ET-743): A Unique Mechanism of Action

  2010cites this paper
• Impact actuel des produits naturels sur la découverte de nouveaux médicaments anticancéreux

  2010cites this paper
• [Current impact of natural products in the discovery of anticancer drugs].

  2010cites this paper
• Action A Review of Trabectedin ( ET-743 ) : A Unique Mechanism of Updated

  2010cites this paper
• Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.

  2010cites this paper
• Actionof Trabectedin (ET-743): A Unique Mechanism of

  2010cites this paper
• eview of Trabectedin ( ET-743 ) : A Unique Ther hanism of Action zio

  2010cites this paper
• Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.

  2009cites this paper
• Translocation-related sarcomas.

  2009cites this paper
• Pharmacotherapy of sarcoma

  2009cites this paper
• In vitro radiosensitisation by trabectedin in human cancer cell lines.

  2008cites this paper
• Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.

  2008cites this paper
• Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.

  2007cites this paper
• Novel marine-derived anti-cancer agents.

  2007cites this paper
• Modulation of gene transcription by natural products--a viable anticancer strategy.

  2007cites this paper
• Extreme sensitivity to Yondelis® (Trabectedin, ET‐743) in low passaged sarcoma cell lines correlates with mutated p53

  2007cites this paper
• Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

  2006cites this paper
• Natural products from marine invertebrates and microbes as modulators of antitumor targets.

  2006cites this paper
• Inhibition of RecBCD enzyme by antineoplastic DNA alkylating agents.

  2006cites this paper
• ET-743: a novel agent with activity in soft-tissue sarcomas

  2006cites this paper
• ET-743: a novel agent with activity in soft tissue sarcomas.

  2005cites this paper
• A Novel Agent with Activity in Soft Tissue Sarcomas

  2005cites this paper
• DNA Structural Similarity in the 2:1 Complexes of the Antitumor Drugs Trabectedin (Yondelis) and Chromomycin A3 with an Oligonucleotide Sequence Containing Two Adjacent TGG Binding Sites on Opposing Strands

  2005cites this paper
• The Discovery of Anticancer Drugs From Natural Sources

  2005cites this paper
• Role of new chemotherapy agents in soft tissue sarcoma.

  2005cites this paper
• Effects of anticancer drugs on transcription factor–DNA interactions

  2005influential citation
• Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters

  2005cites this paper
• SV40 DNA replication inhibition by the monofunctional DNA alkylator Et743.

  2004cites this paper
• Advanced preclinical and clinical trials of natural products and related compounds from marine sources.

  2004cites this paper
• New Drugs from the Sea

  2004cites this paper
• DNA and the chromosome – varied targets for chemotherapy

  2004influential citation
• Marine natural products and related compounds in clinical and advanced preclinical trials.

  2004cites this paper
• Suppression of the Human Parathyroid Hormone Promoter by Vitamin D Involves Displacement of NF-Y Binding to the Vitamin D Response Element*

  2004cites this paper
• The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.

  2004cites this paper
• Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

  2004cites this paper
• Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

  2003cites this paper
• Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin

  2003cites this paper
• Transcription factors as targets for DNA-interacting drugs.

  2003cites this paper
• Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

  2003cites this paper
• Preclinical and clinical results with the natural marine product ET-743

  2003cites this paper
• A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

  2002cites this paper
• Unique features of the mode of action of ET-743.

  2002cites this paper
• Transcription factors and neoplasia: vistas in novel drug design.

  2002cites this paper
• Ecteinascidin-743 inhibits activated but not constitutive transcription.

  2002influential citation
• Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

  2002cites this paper
• Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action

  2002cites this paper
• Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.

  2002cites this paper
• Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat.

  2002cites this paper
• Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics.

  2002cites this paper
• Differential Cytostatic and Apoptotic Effects of Ecteinascidin-743 in Cancer Cells

  2002cites this paper
• Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man

  2001cites this paper
• Phase I and Pharmacokinetic Study of Ecteinascidin 743 Administered as a 72-Hour Continuous Intravenous Infusion in Patients with Solid Malignancies 1

  2001cites this paper
• Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.

  2001cites this paper
• Marine pharmacology in 1999: antitumor and cytotoxic compounds.

  2001cites this paper
• Unique pattern of ET‐743 activity in different cellular systems with defined deficiencies in DNA‐repair pathways

  2001cites this paper
• Delivery systems for DNA-binding drugs as gene expression modulators.

  2001cites this paper
• Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

  2001cites this paper
• Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.

  2001cites this paper
• Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.

  2001cites this paper
• Beta-phenylethylamines and the isoquinoline alkaloids.

  2001cites this paper
• NF-Y regulates LIF-induced transcription of the signaling adaptor SKAP55R in myeloid cells

  2001cites this paper
• Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study 1

  2000cites this paper
• Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

  2000cites this paper
• Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions?

  2000cites this paper
• Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.

  2000cites this paper